- About Us
- Our Story
- Our Products
- Our Science
- Our People
- Our Citizenship
-
Investors
- Reports and Filings
- Presentations
-
Shares
- Share Price
- Stock Updates
- Equity & Dividend History
- Unpaid & Unclaimed Dividend
- Analyst Coverage
- Shareholding Pattern
- Share Transfer Information
- Buyback
- Details of Shares for transfer to IEPF May 2018
- Notice pursuant to IEPF Rules, May 2018
- Details of Shares for transfer to IEPF May 2019
- Notice Pursuant to IEPF Rules, May 2019
- Details of Shares for transfer to IEPF May 2020
- Notice pursuant to IEPF Rules, May 2020
- Governance
- Investor Services
- Media
- Partners
- Canada
- Australia
- Germany
- India
- New Zealand
- China
- Netherlands
- Spain
- Contact Us
Press Releases
Nov
Oct
- Dr. Reddy's expands portfolio in Russia & CIS through in-licensing deals.
- Dr. Reddy's Q2 FY11 Financial Results: Revenue at Rs. 18.7 billion ($420 million); (Growth » 2% YoY & 11% QoQ)
- Dr. Reddy's announces the approval of Lansoprazole delayed-release capsules
- Dr. Reddy's to release Q2 FY11 results on October 23, 2010; Earnings call slated for October 23, 5:00 PM IST / 7.30 AM EST
Jul
Jun
May
- Dr. Reddy’s announces the Launch of Tacrolimus Capsules, the generic version of Prograf®
- Dr. Reddy’s FY10 Financial Results, Revenues at Rs. 70.3 billion ($1.56 billion), EBITDA Adjusted* at Rs. 15.8 billion ($352 million), Profits after Tax Adjusted* at Rs. 9.2 billion ($205 million)
- Dr. Reddy's to release Q4 & Full Year FY10 results on May 6, 2010 Earnings call slated for May 6, 6.30 PM IST / 9.00 AM EST
Apr
Mar
Jan
- Dr. Reddy’s Q3 FY10 Financial Results: Revenues at Rs. 17,296 million;
- Dr. Reddy's to release Q3 FY10 results on Jan 20, 2010 Earnings call slated for Jan 20, 6.30 PM IST / 8.00 AM EST
- Dr. Reddy's and Rheoscience announce headline results from First Phase III clinical trial of Balaglitazone (DRF 2593)
